Proposing that a blend of the chemical diversity of small synthetic molecules with the immunological characteristics of the antibody molecule will lead to therapeutic agents with superior properties, we here present a device that equips small synthetic molecules with both effector function and long serum half-life of a generic antibody molecule. As a prototype, we developed a targeting device that is based on the formation of a covalent bond of defined stoichiometry between a 1,3-diketone derivative of an integrin ␣v␤3 and ␣v␤5 targeting Arg-Gly-Asp peptidomimetic and the reactive lysine of aldolase antibody 38C2. The resulting complex was shown to (i) spontaneously assemble in vitro and in vivo, (ii) selectively retarget antibody 38C2 to the surface of cells expressing integrins ␣v␤3 and ␣v␤5, (iii) dramatically increase the circulatory half-life of the Arg-Gly-Asp peptidomimetic, and (iv) effectively reduce tumor growth in animal models of human Kaposi's sarcoma and colon cancer. This immunotherapeutic has the potential to target a variety of human cancers, acting on both the vasculature that supports tumor growth as well as the tumor cells themselves. Further, by use of a generic antibody molecule that forms a covalent bond with a 1,3-diketone functionality, essentially any compound can be turned into an immunotherapeutic agent thereby not only increasing the diversity space that can be accessed but also multiplying the therapeutic effect.
S
ince Ehrlich's recognition of the potential of antibodies as therapeutic agents in the early 20th century (1), the development of monoclonal antibody (mAb) technology by Köhler and Milstein in the 1970s (2) , and advances in antibody engineering since then (3), mAbs have gained importance for the treatment of a variety of diseases. In addition to a dozen mAbs approved by the U.S. Food and Drug Administration, a considerable number of biotechnology drugs in development are mAbs (4, 5) . The mounting success of the antibody molecule as therapeutic agent is based on at least three properties; (i) a Fab moiety that permits antigen binding with high specificity and affinity, (ii) a Fc moiety that mediates effector functions, such as antibody-dependent cellular cytotoxicity (6) , and (iii) a molecular mass of at least 150 kDa that permits a circulatory half-life of up to 21 days (7). By contrast, conventional therapeutic agents based on small synthetic molecules are clearly limited with respect to their short half-life in circulation, particularly in chronic treatment regimens like those needed in cancer therapy, and their inability to mediate effector functions. However, small synthetic molecules provide an unlimited chemical diversity provided through their isolation as natural products or de novo chemical synthesis and might be expected to eventually outperform mAbs in terms of specificity and affinity of antigen binding. It can further be anticipated that a blend of the unlimited chemical diversity of small synthetic molecules with the longer serum half-life and the effector function of an antibody molecule will lead to therapeutic agents with superior properties (Table 1) .
Here we present a conceptually new device that equips small synthetic molecules with both effector function and long serum half-life of a generic antibody molecule. Mabs have been suggested as carrier proteins of small synthetic molecules (8) . In contrast to earlier studies (9-13), our approach is unique in that small synthetic molecules and mAb form a reversible covalent bond capable of reprogramming the specificity of the antibody both in vitro and in vivo, greatly expanding the scope of potential therapeutic applications of this approach.
As a prototype, we developed a targeting device that is based on the formation of a reversible covalent bond between a diketone derivative of an integrin targeting Arg-Gly-Asp (RGD) peptidomimetic and the reactive lysine of mAb 38C2. mAb 38C2 belongs to a group of catalytic antibodies that were generated by reactive immunization and mechanistically mimic natural aldolase enzymes (14, 15) . Through a reactive lysine, these antibodies catalyze aldol and retro-aldol reactions using the enamine mechanism of natural aldolases (14) (15) (16) (17) (18) . In addition to their remarkable versatility and efficacy in synthetic organic chemistry (reviewed in ref. 14) , aldolase antibodies have been used for the activation of prodrugs in vitro and in vivo (19) (20) (21) (22) . Yet another feature of these antibodies, namely their ability to form a reversible covalent bond with 1,3-diketones by using an enamine docking mechanism (14-16) has remained largely unexplored in terms of potential applications.
Materials and Methods
Synthesis of SCS-873. SCS-873 was synthesized in a sequence of 13 steps starting from the commercially available 3-methyl-4-bromo anisole. Methods used for the synthesis of the parent SmithKline Beecham compound (23) were modified to prepare the amine precursor of SCS-873. An activated N-hydroxysuccinimide ester of 4Ј-glutaramidophenyl hexane-3,5-dione was then reacted with the amine to provide the compound SCS-873 (S.C.S., C.R., C.F.B. III, and R.A.L., unpublished data). from American Tissue Culture Collection. All mouse cell lines were maintained in DMEM supplemented with 4 mM Lglutamine͞1.5 g/liter sodium bicarbonate͞4.5 g/liter glucose͞1 mM sodium pyruvate͞10% FCS, and antibiotics. FITCconjugated goat anti-mouse IgG (HϩL) polyclonal antibodies were from Jackson ImmunoResearch. mAb 38C2 has been described (15) and is commercially available from Sigma. 
Results and Discussion
To show that a targeting module derivatized with a 1,3-diketone linker can reprogram the specificity of mAb 38C2 through reaction with its catalytic lysine residue (Fig. 1A) , compound SCS-873 was synthesized (Fig. 1B) . Applying the concept of reactive immunization (reviewed in ref. 14) , we have shown that the immune system selects antibodies with reactive lysine residues based on their chemical reactivity with 1,3-diketone haptens. The pK a of the reactive lysine is perturbed by a hydrophobic microenvironment, rendering it unprotonated at neutral pH (pK a Ͻ7). experiments with derivatives of the RGD peptidomimetic that did not contain a 1,3-diketone confirmed that this moiety is required for binding of SCS-873 to mAb 38C2 (data not shown). We went on to show that, after independent i.p. and i.v. injections, respectively, SCS-873 and 38C2 form an integrin targeting conjugate in vivo, which was detectable for Ϸ1 week (Fig. 2B) . Sera from control mice treated with an isotype matched mAb lacking the reactive lysine of 38C2 failed to show a cell binding complex (Fig. 2C) . Further, no traces of SCS-873 could be observed by flow cytometry following attempted rescue of the small molecule by addition of mAb 38C2 to the collected sera (data not shown), suggesting that the serum half-life of SCS-873 in the absence of mAb 38C2 is similar to the serum half-life of its parental compound, which was determined to be Ϸ15 min (23) . Based on catalytic activity, we had previously determined a mouse serum half-life of i.v. injected mAb 38C2 of Ϸ4 days showing an in vivo clearance rate with an exponential decay slope (19) . The analysis of the decline of the mean fluorescence intensity over time revealed a similar clearance rate for the 38C2͞SCS-873 complex with a half-life of Ϸ3 days (Fig.  2B) . Thus, the circulatory half-life of SCS-873 was extended by more than two orders of magnitude through binding to mAb 38C2.
The parental compound of SCS-873 binds to both integrins ␣ v ␤ 3 and ␣ v ␤ 5 with nanomolar affinity (23) . Both integrins are expressed on the surface of a variety of tumor cells and are also up-regulated on angiogenic endothelial cells that infiltrate tumors in the course of neovascularization (24) . Small molecule antagonists of integrin ␣ v ␤ 3 and ␣ v ␤ 5 (25) , such as RGD peptidomimetics, interfere with the binding of the integrins to extracellular matrix proteins and, thereby, initiate endothelial cell apoptosis and inhibit angiogenesis (26) . Consequently, integrin ␣ v ␤ 3 and ␣ v ␤ 5 antagonists are promising therapeutic agents in diseases involving neovascularization, such as cancer, diabetic retinopathy, and rheumatoid arthritis. It should be noted that study of small molecule antagonists, like the one we have studied here for modification, typically suffer from poor pharmacokinetics and are typically administered in animal models at very high doses or by continuous pump-based delivery strategies (27) (28) (29) (30) (31) (32) . Based on the cross-reactivity of the 38C2͞ SCS-873 complex with integrins ␣ v ␤ 3 and ␣ v ␤ 5 and the dual expression of integrins ␣ v ␤ 3 and ␣ v ␤ 5 on tumor cells and their supporting vasculature in some cancers, such as KS, melanoma, ovarian, and metastatic breast cancer, the 38C2͞SCS-873 complex is expected to direct multiple therapeutic strikes against cancer, with respect to both target and mechanism, with a single drug. To study the 38C2͞SCS-873 complex in a relevant animal model of cancer, we have used a xenograft of the human KS cell line SLK in nude mice. Our earlier studies of KS have used this model to examine the efficacy of integrin ␣ v ␤ 3 targeted therapy mediated by an in vitro evolved human antibody named JC-7U (33) . Furthermore, to dissect out antitumor and antiangiogenic effects, the 38C2͞SCS-873 complex was also evaluated in a xenograft model of human colon cancer. As noted above, both integrins ␣ v ␤ 3 and ␣ v ␤ 5 are highly expressed on the surface of SLK cells (ref. 33 and data not shown). Thus, in the KS model, both human tumor cells and mouse tumor endothelial cells are targeted by the 38C2͞SCS-873 complex. It should be noted that application of the 38C2͞SCS-873 complex in human therapy to AIDS-related KS would be expected to impact KS proliferation by the additional mechanism of blocking the interaction of the HIV type 1 Tat protein with ␣ v ␤ 3 and ␣ v ␤ 5 (34) .
Treatment of the SLK xenograft in nude mice with the 38C2͞SCS-873 complex formed in vivo revealed a significant decrease in tumor growth as compared with SCS-873 alone or mAb 38C2 alone (Fig. 3A) . By using the same regimen, a SW1222 xenograft in nude mice was treated next. In contrast to human KS cell line SLK, the human colon cancer cell line SW1222 does not express integrin ␣ v ␤ 3 or ␣ v ␤ 5 (data not shown). However, tumor growth was drastically reduced in the presence of the 38C2͞SCS-873 complex, whereas SCS-873 alone or mAb 38C2 alone had no effect (Fig. 3B) . Thus, in the colon cancer model, the 38C2͞SCS-873 complex is likely to mediate its tumor growth inhibition by an antiangiogenic effect directed against the mouse tumor endothelial cells. Most importantly, as both mouse tumor models clearly show, SCS-873 alone, which has a much shorter half-life and cannot trigger antibody-dependent cellular cytotoxicity, is significantly less effective than the 38C2͞SCS-873 complex in inhibiting tumor growth. Furthermore, comparison of the therapeutic efficacy of the 38C2͞SCS-873 complex in the KS model with our previously reported therapeutic studies involving the in vitro evolved human antibody JC-7U (33) , indicates that it is superior. Thus, the chemically programmed antibody developed here outperforms both its small molecule and traditional monoclonal antibody counterparts. Additionally, our study revealed no obvious signs of toxicity for the 38C2͞ SCS-873 complex as indicated by no weight loss or behavioral change during the course of therapy.
To further examine the mechanism by which the 38C2͞SCS-873 complex inhibits tumor growth, we carried out a series of proliferation assays in vitro (Fig. 4) . It was found that both free SCS-873 and 38C2͞SCS-873 complex inhibit the proliferation of human KS SLK cells with an IC 50 of Ϸ1 M (Fig. 4A ). This concentration is below the theoretical peak concentrations of 30 M SCS-873 (0.5 mg per 20 ml mouse body volume) and 2 M 38C2 (0.5 mg per 1.5 ml mouse blood volume) achieved after i.p. and i.v. injection, respectively. Thus, the prolonged serum halflife of cytotoxic SCS-873 in the presence of 38C2 sufficiently explains the tumor growth inhibition in the SLK xenograft, even though antibody-dependent cellular cytotoxicity is likely to be a contributing factor (6) . A complete dose͞response study may aid in unraveling these effects further. As expected from the SW1222 xenograft, SCS-873 also inhibits the proliferation of mouse endothelial cells but not human colon cancer SW1222 cells (Fig. 4B) , suggesting an antiangiogenic effect in this model.
A key element of our approach is the reversible covalent bond between mAb and the small synthetic molecule. In general, the stronger the interaction, the longer is the circulatory half-life of the small synthetic molecule. Using surface plasmon resonance, the k off of the interaction of 38C2 and a 1,3-diketone attached to a linker similar to the linker used for SCS-873 was determined to be Ϸ1 ϫ 10 Ϫ4 s
Ϫ1
(data not shown), which translates into a half-life (ln2͞k off ) of Ϸ2 h for the 38C2͞SCS-873 complex. Although the interaction is strong, its reversibility warrants a slow drug release, resulting in a low free drug concentration that is maintained over a prolonged period. The in vivo circulatory half-life of the complex, however, was Ϸ3 days (Fig. 2B) . The transient nature of the complex also likely suppresses its potential immunogenicity, although hapten-antibody complexes are not known to be particularly immunogenic. Generic design is another key element. In principle, 1,3-diketone derivatives of any small synthetic molecule can be synthesized. In addition, appropriate 1,3-diketone linkers can be covalently attached to a variety of therapeutically relevant macromolecules, such as proteins or peptides, RNA or DNA aptamers, or combinations therein. Most importantly, the antibody molecule in our two-component system is generic. In other words, the same mAb, preferentially a humanized derivative of mAb 38C2 (35) , can be used for a multitude of therapeutic applications, ranging from a mere prolongation of the circulatory half-life to tumor targeting. Among the many therapeutic advantages small synthetic molecules gain through mAb docking (Table 1) , blocking of extracellular protein-protein interactions should be pointed out. The development of small synthetic molecules that antagonize protein-protein interactions has proven to be very difficult (36) . The much larger mAb molecule, on the other hand, is adept at blocking protein-protein interactions. Thus, the docking mechanism presented here may rescue a number of small synthetic molecules that despite high specificity failed as antagonists of extracellular protein-protein interactions.
